Affinity Asset Advisors, LLC 13F holdings, Q2 2025
Holdings as of June 30, 2025 · filings on SEC EDGAR · latest filing →
Affinity Asset Advisors, LLC disclosed 77 US equity positions worth $676.3m in its Q2 2025 13F filing. The largest position was VRNA at 8.5% of the reported book, followed by INSM and XENE. Against the Q1 2025 filing, it opened 7 new positions, added to 17 and reduced 15 among the top 50 holdings.
What did Affinity Asset Advisors, LLC own in Q2 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2025 |
|---|---|---|---|---|---|---|---|
| 1 | VRNA VERONA PHARMA PLC | 8.5% | $57.7m | 610,000 | -1% | reduced | |
| 2 | INSM INSMED INC | Healthcare | 7.1% | $47.8m | 475,000 | 239% | added |
| 3 | XENE XENON PHARMACEUTICALS INC | Healthcare | 5.1% | $34.4m | 1,100,000 | -17% | reduced |
| 4 | ACLXGBX ARCELLX INC | 4.8% | $32.6m | 495,000 | -7% | reduced | |
| 5 | 2655787D BLUEPRINT MEDICINES CORP | 4.7% | $32.0m | 250,000 | – | new | |
| 6 | NUVALENT INC | 4.7% | $31.7m | 415,000 | -10% | reduced | |
| 7 | APGE APOGEE THERAPEUTICS INC | Healthcare | 4.4% | $30.0m | 691,899 | -40% | reduced |
| 8 | ALKS ALKERMES PLC | Healthcare | 4.2% | $28.6m | 1,000,000 | 0% | held |
| 9 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 3.6% | $24.3m | 440,000 | 10% | added |
| 10 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 3.6% | $24.2m | 80,000 | 0% | held |
| 11 | TEVA TEVA PHARMACEUTICAL INDS LTD | Healthcare | 3.5% | $23.5m | 1,400,000 | 0% | held |
| 12 | LXEO LEXEO THERAPEUTICS INC | Healthcare | 2.1% | $14.4m | 3,589,355 | 142% | added |
| 13 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 2.1% | $14.4m | 970,000 | -9% | reduced |
| 14 | ESTA ESTABLISHMENT LABS HLDGS INC | Healthcare | 2.1% | $14.3m | 334,863 | 20% | added |
| 15 | TRVI TREVI THERAPEUTICS INC | Healthcare | 2.0% | $13.9m | 2,534,058 | 103% | added |
| 16 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 1.9% | $13.0m | 2,000,308 | 10% | added |
| 17 | VERA VERA THERAPEUTICS INC | Healthcare | 1.9% | $12.8m | 545,000 | 53% | added |
| 18 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 1.8% | $12.2m | 900,000 | -18% | reduced |
| 19 | CNTA CENTESSA PHARMACEUTICALS PLC | 1.7% | $11.8m | 900,162 | -42% | reduced | |
| 20 | KARYOPHARM THERAPEUTICS INC | 1.7% | $11.6m | 15,250,000 | 0% | held | |
| 21 | NRIX NURIX THERAPEUTICS INC | Healthcare | 1.6% | $11.0m | 967,620 | 19% | added |
| 22 | RZLT REZOLUTE INC | 1.5% | $9.8m | 2,200,000 | 29% | added | |
| 23 | VTYXUSD VENTYX BIOSCIENCES INC | 1.4% | $9.7m | 4,536,182 | – | new | |
| 24 | SYRE SPYRE THERAPEUTICS INC | 1.3% | $9.1m | 606,678 | 26% | added | |
| 25 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 1.2% | $8.0m | 400,000 | – | new |
| 26 | PROQR THRAPEUTICS N V | 1.1% | $7.1m | 3,499,512 | 7% | added | |
| 27 | AKBA AKEBIA THERAPEUTICS INC | Healthcare | 1.0% | $7.1m | 1,950,000 | 30% | added |
| 28 | OMEROS CORP | 1.0% | $7.1m | 9,025,000 | – | new | |
| 29 | INOZYME PHARMA INC | 1.0% | $7.0m | 1,749,359 | -55% | reduced | |
| 30 | AUTL AUTOLUS THERAPEUTICS PLC | Healthcare | 1.0% | $6.9m | 3,045,000 | 0% | held |
| 31 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 1.0% | $6.8m | 603,479 | 11% | added |
| 32 | TVTX TRAVERE THERAPEUTICS INC | 1.0% | $6.7m | 7,000,000 | 0% | held | |
| 33 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 1.0% | $6.5m | 150,000 | -50% | reduced |
| 34 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 0.8% | $5.5m | 390,000 | 0% | held |
| 35 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 0.8% | $5.2m | 50,000 | -50% | reduced |
| 36 | ERAS ERASCA INC | Healthcare | 0.8% | $5.2m | 4,085,787 | 22% | added |
| 37 | NEWAMSTERDAM PHARMA COMPANY | 0.7% | $5.0m | 275,000 | -15% | reduced | |
| 38 | CBIO CRESCENT BIOPHARMA INC. | 0.7% | $4.5m | 280,031 | – | new | |
| 39 | ROIV ROIVANT SCIENCES LTD | Healthcare | 0.7% | $4.5m | 400,000 | 167% | added |
| 40 | CRNXGBP CRINETICS PHARMACEUTICALS IN | 0.6% | $4.4m | 152,252 | 0% | held | |
| 41 | PCVX VAXCYTE INC | Healthcare | 0.6% | $4.1m | 125,000 | 400% | added |
| 42 | PERCEPTIVE CAP SOLUTIONS COR | 0.5% | $3.7m | 350,000 | 0% | held | |
| 43 | MERUS N V | 0.5% | $3.7m | 70,000 | -78% | reduced | |
| 44 | CATX PERSPECTIVE THERAPEUTICS INC | 0.5% | $3.6m | 1,050,000 | -53% | reduced | |
| 45 | AVTX AVALO THERAPEUTICS INC | Healthcare | 0.4% | $3.0m | 607,872 | -7% | reduced |
| 46 | OAKTREE ACQUISITION CORP III | 0.4% | $2.7m | 250,000 | 0% | held | |
| 47 | JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 0.4% | $2.7m | 25,000 | – | new |
| 48 | MNPR MONOPAR THERAPEUTICS INC | 0.4% | $2.4m | 67,500 | 9% | added | |
| 49 | RAPP RAPPORT THERAPEUTICS INC | 0.3% | $2.3m | 199,643 | – | new | |
| 50 | GERN GERON CORP | Healthcare | 0.3% | $2.1m | 1,500,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.